Line of Treatment in Oncology Drug Development

This document is a technical report that discusses the critical role of line of treatment in oncology drug development. It outlines how the positioning of a therapy in first-line, second-line, or later-line settings influences various aspects of clinical trials, including design, enrollment speed, and approval probability. The report presents findings from a benchmark analysis of over 6,000 oncology programs, detailing how treatment lines affect trial endpoints, patient availability, and regulatory expectations. It explains that first-line programs often face stricter scrutiny, requiring more rigorous endpoints, while later-line programs may move faster but risk being overshadowed by new entrants. The report also highlights the historical performance of different treatment lines, noting that while first-line programs show higher early-phase transition rates, Phase 3 success rates are similar across lines. Additionally, it discusses the strategic implications for clinical development teams and portfolio strategists, emphasizing the importance of understanding historical data and predictive modeling in decision-making.